Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | UTRN | P46939 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.31 |
| ▸ | CDK9 | P50750 | 1/20 | 0.31 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15216135 | 1.00 | ALDH1A1 (0.37) | ALDH1A1KMT2ALMNAGAAMEN1 | |
| SCHEMBL313267 | 0.89 | KMT2A (0.40) | ALDH1A1KMT2AGAAMEN1CCNT1 | |
| SCHEMBL15216136 | 0.89 | KMT2A (0.40) | ALDH1A1KMT2AGAAMEN1CCNT1 | |
| SCHEMBL313534 | 0.88 | RXFP1 (0.34) | KMT2ALMNAGAAMEN1P2RX3 | |
| SCHEMBL15216134 | 0.88 | RXFP1 (0.34) | KMT2ALMNAGAAMEN1P2RX3 | |
| SCHEMBL608898 | 0.87 | ADAM17 (0.36) | ALDH1A1KMT2AGAAMEN1CCNT1 | |
| SCHEMBL15216138 | 0.84 | NPSR1 (0.32) | KMT2ALMNAGAAMEN1NPSR1 | |
| SCHEMBL313630 | 0.84 | NPSR1 (0.32) | KMT2ALMNAGAAMEN1NPSR1 | |
| SCHEMBL608882 | 0.83 | HTR2A (0.34) | ALDH1A1KMT2AMEN1CCNT1CDK9 | |
| SCHEMBL14806631 | 0.81 | ADAM17 (0.30) | ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130030209-A1 | PHOSPHINATE RUTHENIUM COMPLEXES | IDENIX PHARMACEUTICALS, INC. (US) | 2013-01-31 | — | — | US | disclosed |
| US-8309737-B2 | Phosphinate ruthenium complexes | IDENIX PHARMACEUTICALS, INC. (US) | 2012-11-13 | — | — | US | disclosed |
| US-20120041191-A1 | PHOSPHINATE RUTHENIUM COMPLEXES | IDENIX PHARMACEUTICALS, INC. (US) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120041191-A1 | PHOSPHINATE RUTHENIUM COMPLEXES | RPIA, NDUFS7, PHOSPHO1 | ALDH1A1 3900/4885KMT2A 4091/4885LMNA 4697/4885 |
| US-20130030209-A1 | PHOSPHINATE RUTHENIUM COMPLEXES | RPIA, NDUFS7, POP1 | ALDH1A1 3489/4885KMT2A 4222/4885LMNA 4670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.